Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: Results of the real-world, clinical practice HCV-TARGET study

Gut

Volumn 66, Issue 10, 2017, Pages 1844-1852

  Welzel, Tania M ^a   Nelson, David R ^b   Morelli, Giuseppe ^b   Di Bisceglie, Adrian ^c   Reddy, Rajender K ^d   Kuo, Alexander ^e   Lim, Joseph K ^f   Darling, Jama ^g   Pockros, Paul ^h   Galati, Joseph S ⁱ   Frazier, Lynn M ^j   Alqahtani, Saleh ^k   Sulkowski, Mark S ^k   Vainorius, Monika ^g   Akushevich, Lucy ^g   Fried, Michael W ^g   Zeuzem, Stefan ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY OF FLORIDA   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

^h SCRIPPS CLINIC   (United States)

ⁱ Liver Specialists of Texas   (United States)

^j Liver Wellness Center   (United States)

^k JOHNS HOPKINS UNIVERSITY   (United States)

more..

Author keywords

Clinical Trials; Genotype; Hepatitis C

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; RIBAVIRIN; SERUM ALBUMIN; SOFOSBUVIR; ANTIVIRUS AGENT;

ABDOMINAL PAIN; ADULT; ANEMIA; ANTIVIRAL THERAPY; ANXIETY; ARTICLE; BACKACHE; BACTERIAL PERITONITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; DEPRESSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EUROPE; FALLING; FATIGUE; FEMALE; FLU LIKE SYNDROME; GASTROENTERITIS; GENERALIZED EDEMA; HEADACHE; HEART ARREST; HEART INFARCTION; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 2; HUMAN; HYPERVOLEMIA; HYPOVOLEMIA; INSOMNIA; LIVER CIRRHOSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; NAUSEA; NORTH AMERICA; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; RELAPSE; SIDE EFFECT; SUSTAINED VIROLOGIC RESPONSE; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; ADOLESCENT; ADVERSE EFFECTS; AGED; COMBINATION DRUG THERAPY; COMPLICATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; METABOLISM; MIDDLE AGED; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RIBAVIRIN; SERUM ALBUMIN; SOFOSBUVIR; SUSTAINED VIROLOGIC RESPONSE; YOUNG ADULT;

EID: 84978906972     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2016-311609     Document Type: Article

References (29)

1. Thomas DL. Global control of hepatitis C: Where challenge meets opportunity. Nat Med 2013;19:850-8.
2. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014;61 (1 Suppl):S58-68.
3. van der Meer AJ, Wedemeyer H, Feld JJ, et al. Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. JAMA 2014;312:1927-8.
4. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-93.
5. Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014;61(1 Suppl):S45-57.
6. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015;61:77-87.
7. Andriulli A, Mangia A, Iacobellis A, et al. Meta-analysis: The outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther 2008;28:397-404.
8. Welzel TM, Dultz G, Zeuzem S. Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors. J Hepatol 2014;61(1 Suppl):S98-S107.
9. Kumar S, Jacobson IM. Antiviral therapy with nucleotide polymerase inhibitors for chronic hepatitis C. J Hepatol 2014;61(1 Suppl):S91-7.
10. Sovaldi (sofosbuvir) prescribing information. Foster City, CA: Gilead Sciences, 2014 (package insert). (http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi-pi.pdf ).
11. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-87.
12. Jacobson IM, Gordon SC, Kowdley KV, et al., POSITRON Study; FUSION Study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368:1867-77.
13. Zeuzem S, Dusheiko GM, Salupere R, et al., VALENCE Investigators. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014;370:1993-2001.
14. AASLD/IDSA HCV Guidance Panel. Hepatitis C Guidance: AASLD-IDSA Recommendations for Testing, Managing, and Treating Adults Infected With Hepatitis C Virus. Hepatology 2015;62:932-54.
15. Myers RP, Shah H, Burak KW, et al. Re: RP Myers, H Shah, KW Burak, et al. An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol 2015;29:19-34.
16. European Association for Study of Liver. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol 2014;60:392-420.
17. Sarrazin C, Berg T, Buggisch P, et al. [S3 guideline hepatitis C addendum]. Z Gastroenterol 2015;53:320-34.
18. Dieterich D, Bacon B, Flamm S, et al. P0775: Final evaluation of 955 HCV patients treated with 12 week regimens containing sofosbuvir +/simeprevir in the trio network: Academic and community treatment of a real-world, heterogeneous population. J Hepatol 2015;62:S621.
19. Backus LI, Belperio PS, Shahoumian TA, et al. Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans. Aliment Pharmacol Ther 2015;42:559-73.
20. http://www.hcvtarget.org (accessed on 01/09/2016).
21. Sulkowski MS, Vargas HE, Di Bisceglie AM, et al., HCV-TARGET Study Group. Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. Gastroenterology 2016;150:419-29.
22. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377-81.
23. Foster GR, Pianko S, Brown A, et al., BOSON Study Group. Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients with Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection. Gastroenterology 2015;149:1462-70.
24. Reddy KR, Bourlière M, Sulkowski M, et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. Hepatology 2015;62:79-86.
25. Deterding K, Höner Zu Siederdissen C, Port K, et al. Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies. Aliment Pharmacol Ther 2015 Oct;42:889-901.
26. Charlton M, Everson GT, Flamm SL, et al., SOLAR-1 Investigators. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology 2015;149:649-59.
27. Karchava M, Waldenström J, Parker M, et al. High incidence of the hepatitis C virus recombinant 2k/1b in Georgia: Recommendations for testing and treatment. Hepatol Res 2015;45:1292-8. Dec.
28. Feld JJ, Jacobson IM, Hézode C, et al., ASTRAL-1 Investigators. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med 2015;373:2599-607.
29. Foster GR, Afdhal N, Roberts SK, et al., ASTRAL-2 Investigators; ASTRAL-3 Investigators. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med 2015;373:2608-17.